Sep 11, 2024 – Sep 13, 2024

8th World Congress on Controversies in Breast Cancer (CoBrCa)

Edinburgh, Scotland, UK

Meet the Veracyte® Breast Cancer team at the 8th World Congress on Controversies in Breast Cancer (CoBrCa) at Booth #12!

Breakfast Symposium supported by Veracyte:
“What is the true utility of Genomic Testing in Early Breast Cancer? A closer look at intrinsic subtyping and Prosigna.”
Thursday, September 12
07:30 am – 08:30 am
Hall A
Chair: Prof Dame Lesley Fallowfield
Speakers:
  • Professor Matt EllisThe clinical utility of PAM50 and intrinsic subtyping and a comparison of the available technologies
  • Professor Stuart McIntoshPrognostication vs Prediction. A review of the available evidence and a discussion around the value of the OPTIMA study
  • Professor Dame Lesley FallowfieldHow well do healthcare professionals and patients understand the information provided by genomic test reports?
Learn more about the Prosigna® Breast Cancer Assay, the breast cancer risk of recurrence test that confidently guides treatment decisions.

RELEVANT PRODUCTS

Prosigna Breast Cancer Assay

The Prosigna® Breast Cancer Assay

THE TEST to answer more than one question.